DOI: 10.1055/s-00000142

Frauenheilkunde up2date


Gelber RD, Goldhirsch A, Piccart M et al.
HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. ESMO Congress 2012; Abstract LBA6: presented October 1; 2012.

Download Bibliographical Data